Clinical trial · Interventional
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma
NCT05764954CI-TRIAL-00112860active not recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of Lung | Lung Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NovoTTF-200T System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- NovoTTF-200T System Tumor-Treating Fields (TTFields)
- description
- Following pathological confirmation on of lung ADC, patients will proceed with TTFields treatment. The NovoTTF-200T System is an investigational medical device delivering 150 kHz TTFields to the patient's chest. The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
- interventionNames
- Device: NovoTTF-200T System
Primary outcomes (1)
- measure
- Adverse events, severity and frequency
- timeFrame
- 1 year
- description
- based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 22 Years
Show eligibility criteria text
Inclusion Criteria: * The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection. * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy. * The participant with multiple nodules has one nodule that meets the criteria. * The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy. Exclusion Criteria: * Patients receiving therapy for concurrent active malignancy * Patients with a history of cardiac arrhythmias and/or pacemaker use * Patients with lung nodules \<1cm * Patients with lung nodules that are pure ground glass opacities (GGOs) of any size * Patients with lung nodules that are \<50% solid of any size
References
Publications (0)
Data not yet available
No reference posted for this study.